Scribe Therapeutics is a clinical-stage biotechnology company that develops in vivo CRISPR-based genetic medicines for cardiovascular and metabolic diseases. Scribe focuses on atherosclerotic cardiovascular disease, aiming to replace chronic medications with single or limited-course treatments that address root genetic drivers. The company's technology platform is built on a proprietary CasX enzyme and includes two primary modalities: ELXR for epigenetic silencing and XE for gene editing. ELXR suppresses gene expression without permanently altering DNA sequences, while XE enables permanent editing of disease-causing genes. Scribe's lead candidate, STX-1150, is a Phase 1 epigenetic silencer designed to lower LDL cholesterol. Scribe also develops preclinical programs, STX-1200 and STX-1400, to target lipoprotein(a) and triglycerides. Scribe operates a hybrid business model that pairs internal drug development with pharmaceutical partnerships. Scribe licenses its technology to companies such as Lilly and Sanofi for use in non-core disease areas. These collaborations provide upfront and milestone payments that fund Scribe's wholly-owned pipeline. Scribe uses lipid nanoparticles to deliver its therapies to the liver and utilizes a machine-learning-driven engineering process to optimize molecules for specific therapeutic targets.